FGFR4 inhibitor acid salts and their preparation and use

The p-toluenesulfonate salt form of the FGFR4 inhibitor addresses solubility and bioavailability issues, enabling effective clinical and industrial use for cancer treatment.

JP2024544707AActive Publication Date: 2024-12-03ABBISKO THERAPEUTICS CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024534767
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-13
Filing Date
2022-12-12
Publication Date
2024-12-03
Estimated Expiration
2042-12-12

AI Technical Summary

Technical Problem

Existing FGFR4 inhibitors, such as the compound represented by formula (I), suffer from poor solubility and bioavailability, making them unsuitable for clinical and industrial drug development.

Method used

Development of the p-toluenesulfonate salt form of the FGFR4 inhibitor, which significantly improves solubility and bioavailability, enhancing its suitability for clinical and industrial applications.

Benefits of technology

The p-toluenesulfonate salt form exhibits improved solubility and bioavailability, meeting the demands of clinical drug formulations and industrial production, and is effective in treating various cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544707000001_ABST
    Figure 2024544707000001_ABST
Patent Text Reader

Abstract

The present invention relates to an acid salt of an FGFR4 inhibitor and its preparation and use. The FGFR4 inhibitor is a compound having a structure represented by formula (I) N-((3S,4S)-3-((6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methylazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide, and the acid salt is a p-toluenesulfonate, which can greatly improve the physical and chemical properties such as solubility and bioavailability of the compound represented by formula (I) in free form, and meet the needs of clinical drug formulation development. The p-toluenesulfonate of the present invention has very important clinical use value, and is expected to promote the development of a new family of FGFR4 small molecule inhibitors. [Formula 1] TIFF2024544707000010.tif51170
Need to check novelty before this filing date? Find Prior Art

Description

Detailed Description of the Invention

[0001] [Technical field] The present invention belongs to the field of drug development, specifically, to an acid salt of an FGFR4 inhibitor and its preparation method and use. [Background technology]

[0002] Fibroblast growth factors (FGFs) are a family of 22 structurally related polypeptides with different biological activities, and the corresponding receptors of FGFs (FGFRs) belong to the family of receptor tyrosine kinases, RPTK. Currently, four receptors, FGFR1, FGFR2, FGFR3 and FGFR4, have been found, which initiate downstream multiple signaling cascade reactions involving MAPK and AKT, as their interaction with the corresponding ligand FGF leads to receptor dimerization and autophosphorylation. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in China and is also one of the cancers with the fastest annual increase in incidence. The current first-line treatment regimen is sorafenib, and there is no approved second-line drug, so targeted drugs with anti-cancer agents are still needed. Although 5%-10% of hepatocellular carcinoma patients have overexpression of FGF19, FGFR4 is the dominant FGFR present in human hepatocytes, and its high expression in hepatocytes is thought to correlate with the invasiveness of hepatocellular tumors. Therefore, FGFR4 plays a very important role in liver cancer. The interaction between FGF19 and FGFR4 is also believed to correlate with the invasiveness of other types of cancer (e.g., gastric cancer, prostate cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer).

[0003] At present, highly selective FGFR4 inhibitors can effectively treat cancer diseases caused by abnormalities of the FGFR4 signal pathway, and avoid related side effects such as hyperphosphatemia caused by FGFR1-3 inhibition. Highly selective FGFR4 small molecule inhibitors have great prospects for use in the field of tumor targeted therapy. As a good drug candidate, FGFR4 inhibitors can meet the needs of liver cancer and other tumor targeted drugs in China and abroad, and also bring the advantages of excellent safety and higher specificity.

[0004] Through a long-term research process, Abbisko Therapeutics Co., Ltd. has invented a novel small molecule compound with highly selective FGFR4 inhibitory effect, the relevant patent is WO2018113584A1 (international publication date: June 28, 2018), the representative compounds of which are as follows:

[0005] [ka]

[0006] The compound N-((3S,4S)-3-((6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methylazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide (compound represented by formula (I)) has significantly improved the inhibitory effect of FGFR4 target and selectivity against other FGFR1-3 kinase receptors, and can meet the current needs of tumor targeting treatment of liver cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma or rhabdomyosarcoma in China and abroad.

[0007] However, at the time of filing the patent application, the raw materials and processes suitable for clinical and industrial use have not been developed, and no further research has been done on whether the compound represented by formula (I) is suitable for drug development. Subsequent research by the inventors has found that the free base compound disclosed in WO2018113584A1 is poorly soluble in water and physiological solvents, has relatively low bioavailability, cannot meet clinical requirements, and is not suitable for the development of clinical formulations. Therefore, in order to meet the demands of clinical research and marketed drug formulations, it is urgent to further study the aggregation state of the drug to improve the physical and chemical properties of the compound, meet the demands of pharmaceutical or clinical use, and develop a compound with a salt form or crystalline form that can be adapted for drug development to overcome the deficiencies in the prior art. [Summary of the invention]

[0008] In order to solve the problems in the prior art, the inventors have further studied the aggregation state of the compound represented by formula (I) N-((3S,4S)-3-((6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methylazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide. Through long-term research, the inventors unexpectedly found that p-toluenesulfonate can greatly improve the solubility and bioavailability of the compound represented by formula (I) in free form, and the physical and chemical properties such as hygroscopicity and chemical stability can also meet the needs of industrial production and the needs of clinical drug formulation development. The p-toluenesulfonate salt of the present invention is widely used in the manufacture of drugs for treating cancer, especially liver cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma or rhabdomyosarcoma, and has very important clinical value, which is expected to promote the development of new FGFR4 small molecule inhibitors.

[0009] In a first aspect of the present invention, there is provided a p-toluenesulfonate salt of a compound represented by formula (I).

[0010] [ka]

[0011] In a preferred embodiment, the p-toluenesulfonate salt of the compound represented by the formula (I) is a crystalline compound. In a more preferred embodiment, the X-ray powder diffraction pattern (XRPD) of the compound p-toluenesulfonate represented by the formula (I) includes peaks located at diffraction angles (2θ) of 9.02±0.2°, 17.18±0.2°, 17.68±0.2°, 19.60±0.2° and 22.90±0.2°.

[0012] In a further preferred embodiment, the X-ray powder diffraction pattern (XRPD) of the compound p-toluenesulfonate represented by the formula (I) includes peaks located at diffraction angles (2θ) of 9.02±0.2°, 17.18±0.2°, 17.68±0.2°, 19.60±0.2°, 22.90±0.2°, 10.60±0.2°, 12.72±0.2°, 18.56±0.2°, 21.22±0.2° and 24.90±0.2°.

[0013] In a further preferred embodiment, the X-ray powder diffraction pattern (XRPD) of the compound p-toluenesulfonate represented by the formula (I) includes peaks located at diffraction angles (2θ) of 9.02±0.2°, 17.18±0.2°, 17.68±0.2°, 19.60±0.2°, and 22.90±0.2°, 10.60±0.2°, 12.72±0.2°, 18.56±0.2°, 21.22±0.2°, 24.90±0.2°, 15.32±0.2°, 23.82±0.2°, 24.12±0.2°, 24.60±0.2°, and 25.58±0.2°.

[0014] In a preferred embodiment, the X-ray powder diffraction pattern of the compound p-toluenesulfonate represented by the formula (I) is 9.02±0.2°, 10.60±0.2°, 12.04±0.2°, 12.72±0.2°, 15.32±0.2°, 17.18±0.2°, 17.68±0.2°, 18.56±0.2°, 19.60±0.2°, 20.60±0. The peaks located at diffraction angles (2θ) of 2°, 21.22±0.2°, 22.90±0.2°, 23.82±0.2°, 24.12±0.2°, 24.60±0.2°, 24.90±0.2°, 25.58±0.2°, 27.78±0.2°, 29.04±0.2°, 31.48±0.2°, 36.60±0.2° and 38.16±0.2°.

[0015] In a most preferred embodiment, the X-ray powder diffraction pattern of the compound p-toluenesulfonate represented by formula (I) is essentially the same as the peaks at the diffraction angles (2θ) shown in Table 1, and the diffraction angles (2θ) and related intensity data (±0.2°) are as follows:

[0016] [Table 1]

[0017] In a preferred embodiment, the unit cell of the compound p-toluenesulfonate represented by the formula (I) is P1, a = 9.079(3) Å, b = 10.561(3) Å, c = 10.882(3) Å, and the volume of the unit cell is 908.1(4) Å3.

[0018] In a preferred embodiment, the p-toluenesulfonate of the compound represented by formula (I) is a hydrate.

[0019] In a more preferred embodiment, each molecule of the hydrate of the p-toluenesulfonate salt of the compound represented by the formula (I) contains 1 to 3 water molecules.

[0020] In a more preferred embodiment, each molecule of the hydrate of the p-toluenesulfonate salt of the compound represented by formula (I) contains one, two or three water molecules.

[0021] As the invention-creation of the present application, the applicant designates a crystal of p-toluenesulfonate salt of compound represented by formula (I) having any one of the above X-ray powder diffraction data as crystalline form A (Form A), and the obtained crystal is physically characterized by DSC, TGA and XRPD and shown to be a well-crystalline solid, and the DSC and TGA results, as shown in Figures 1 and 2, indicate that the crystalline form of the acid salt of compound represented by formula (I) is a monohydrate.

[0022] In a second aspect of the present invention, there is provided a method for producing p-toluenesulfonate of the compound represented by formula (I), 1) dissolving or dispersing the compound represented by formula (I) in a free form in an aqueous solvent or an appropriate organic solvent, and adding p-toluenesulfonic acid or a p-toluenesulfonic acid solution to the system to form a salt, or adding the compound represented by formula (I) in a free form to a p-toluenesulfonic acid solution to form a salt; 2) collecting the p-toluenesulfonate of the compound represented by formula (I), which is a solid product precipitated during the reaction for producing a salt, or obtaining the p-toluenesulfonate of the compound represented by formula (I), which is a solid product, by causing supersaturation in the salt production system.

[0023] In a preferred embodiment, the method for causing supersaturation in the salt forming system in the step 2) includes one or more of adding seed crystals, volatilizing the solvent, adding a poor solvent, and lowering the temperature.

[0024] In a preferred embodiment, the p-toluenesulfonate salt of the compound represented by formula (I), which is the solid product obtained above, is a crystalline p-toluenesulfonate salt of the compound represented by formula (I).

[0025] In a preferred embodiment, the suitable organic solvent used in the salt formation process in step 1) is selected from organic solvents of alcohols, chloroalkanes, ketones, ethers, cyclic ethers, esters, alkanes, cycloalkanes, benzenes, amides, sulfoxides, or mixtures thereof.

[0026] In a preferred embodiment, the suitable organic solvent is selected from methanol, ethanol, n-propanol, isopropanol, dichloromethane, acetonitrile, acetone, 1,4-dioxane, tetrahydrofuran, N,N-dimethylformamide, ethyl acetate, isopropyl acetate, methyl tert-butyl ether, 2-methoxyethyl ether or mixtures thereof.

[0027] In a third aspect of the present invention, there is provided a pharmaceutical composition comprising a therapeutically effective amount of the p-toluenesulfonate salt of a compound of formula (I) as described above and a medicament acceptable carrier.

[0028] In a fourth aspect of the present invention, there is provided the use of the p-toluenesulfonate salt of the compound of formula (I) in the manufacture of an FGFR4 inhibitor medicament.

[0029] In a fifth aspect of the present invention, there is provided the use of p-toluenesulfonate salt of compound of formula (I) in the manufacture of a medicament for treating liver cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma or rhabdomyosarcoma.

[0030] In a sixth aspect of the present invention, there is provided a method for treating liver cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma or rhabdomyosarcoma, comprising administering to a patient in need of such treatment a therapeutically effective amount of p-toluenesulfonate of the compound represented by formula (I) or the pharmaceutical composition. [Brief description of the drawings]

[0031] [Figure 1]1 is a differential scanning calorimetry diagram of the p-toluenesulfonate salt (Form A) of the compound represented by formula (I), in which the X-axis is temperature (° C.) and the Y-axis is heat flow (W / G). [Diagram 2] 1 is a thermogravimetric analysis diagram of p-toluenesulfonate (Form A) of the compound represented by formula (I), in which the X-axis represents temperature (° C.) and the Y-axis represents the weight loss rate (%). [Diagram 3] 1 is an X-ray powder diffraction pattern of the p-toluenesulfonate salt (Form A) of the compound represented by formula (I), in which the X-axis represents the diffraction peak angle 2θ value (°) and the Y-axis represents the peak intensity. [Figure 4] The X-ray diffraction simulated powder diffraction pattern (bottom) of a single crystal of p-toluenesulfonate (Form A) of the compound represented by formula (I) and the measured XRPD pattern (top) of p-toluenesulfonate (Form A) of the compound represented by formula (I). The abscissa represents the 2θ value (°), and the ordinate represents the peak intensity. [Diagram 5] FIG. 2 is a unit cell diagram of a single crystal of p-toluenesulfonate (Form A) of the compound represented by formula (I). [Figure 6] 1 is a DVS pattern of the p-toluenesulfonate salt of the compound represented by formula (I) (Form A). The abscissa represents relative humidity (%), and the ordinate represents weight change (%). [Figure 7] 1 shows the time / solubility curves of the p-toluenesulfonate salt (Form A) of the compound of formula (I) and the free form of the compound of formula (I) in a 25% PEG300 / 5% Solutol HS15 / 70% water solvent. The abscissa is time (hours) and the ordinate is concentration (mg / mL). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0032] [Specific embodiment] Depending on the crystalline form of a drug, the bioavailability, solubility, melting point, chemical and physical stability, etc. differ, which further affects the safety and efficacy of the drug. In order to develop a salt form or crystal form suitable for drug development, the inventors have intensively studied the compound represented by formula (I), N-((3S,4S)-3-((6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methylazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide, and screened a large number of salt forms and crystal forms for the compound represented by formula (I). It was found that the p-toluenesulfonate salt can greatly improve the physical and chemical properties such as solubility and bioavailability of the compound represented by formula (I) in the free form, and the physical and chemical properties such as hygroscopicity and chemical stability can also meet the needs of industrial production and the needs of clinical drug formulation development, which is expected to promote the development of a new generation of FGFR4 small molecule inhibitors.

[0033] DETAILED DESCRIPTION: Unless stated to the contrary, terms used in the following specification and claims shall have the following meanings.

[0034] A "pharmaceutical composition" refers to a mixture of one or more compounds described herein, or physiologically / pharmaceutical acceptable salts or prodrugs thereof, and other chemical components, including other components such as physiologically / pharmaceutical acceptable carriers and excipients, to facilitate administration to a living body and to contribute to the absorption of the active ingredients to further exert biological activity.

[0035] "Polycrystalline forms" refer to crystalline forms that have the same chemical composition but different spatial arrangements of the molecules, atoms and / or ions that compose the crystal. Although polycrystalline forms have the same chemical composition, their packing and geometric arrangements are different and may exhibit different physical properties such as melting point, shape, color, density, hardness, deformability, stability, solubility, dissolution rate and similar properties. Both polycrystalline forms may be monotropic or tautomeric depending on their temperature-stability relationship. In a monotropic system, the relative stability between the two solid phases remains unchanged with changes in temperature. Conversely, in a tautomeric system, a transition temperature exists where the stability of the two phases switches. The phenomenon of such compounds existing in different crystal structures is called the drug polycrystalline phenomenon.

[0036] The various crystalline structures of the present invention can be distinguished from one another using various analytical techniques known to those skilled in the art, including, but not limited to, X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and / or thermogravimetric analysis (TGA).

[0037] Methods and Materials 1.1 X-ray powder diffraction Those skilled in the art will recognize that X-ray powder diffraction patterns may be obtained under measurement errors that depend on the measurement conditions used. The intensity of the X-ray powder diffraction pattern may vary depending on the conditions of the material used. The relative intensity may also vary depending on the experimental conditions, and correspondingly, the exact intensity is not taken into account. In addition, the measurement error of the conventional X-ray powder diffraction angle is usually about 5% or less, and such measurement error is considered to be applicable to the diffraction angle. Therefore, the crystal structure of the present invention is not limited to a crystal structure that provides an X-ray powder diffraction pattern that is completely the same as the X-ray powder diffraction pattern shown in the drawings disclosed herein. Any crystal structure that has an X-ray powder diffraction pattern that is basically the same as that disclosed in the drawings is included in the scope of the present invention. Those skilled in the art should have the ability to determine that the X-ray powder diffraction pattern is basically the same as the X-ray powder diffraction pattern. Other suitable standard calibrations known to those skilled in the art. However, the relative intensity may vary depending on the size and shape of the crystal.

[0038] The crystalline forms of the compounds according to the invention were characterized by their X-ray powder diffraction patterns. Thus, the X-ray powder diffraction patterns of the salts were obtained on a Bruker D8 Discover X-ray powder diffractometer with a GADDS (General Area Diffraction Detector System) CS operating in reflection mode using Cu Kα radiation (1.54 Å). Scans were performed with a tube voltage of 40 kV and a current of 40 mA. The samples were scanned for 60 seconds within the 2θ range of 3.0° to 40°. The diffractometer was calibrated with a corundum standard for peak positions expressed in terms of 2θ. All analyses were typically performed at 20°C to 30°C. Data were acquired and integrated using GADDS for 4.1.14T version WNT software. DiffracPlus software with 9.0.0.2 version Eva published in 2003 was used to analyze the diffraction patterns.

[0039] Preparation of XRPD samples was typically performed by placing the sample on single crystal silicon and pressing the sample powder with a glass plate or equivalent to ensure that the sample surface was flat and had the appropriate height. The sample holder was then placed in a Bruker XRPD instrument, and an X-ray powder diffraction pattern was acquired using the instrument parameters described above. Measurement differences associated with the results of such X-ray powder diffraction analyses arose from multiple factors, including (a) errors in sample preparation (e.g., sample height), (b) instrument errors, (c) calibration differences, (d) operator errors (including errors incurred when measuring peak positions), and (e) material properties (e.g., preferred orientation errors). Calibration errors and sample height errors often result in all peaks shifting in the same direction. Typically, this calibration factor will match the measured peak positions with the expected peak positions, and may be within the expected 2θ value of ±0.2°.

[0040] 1.2. Differential scanning calorimetry (DSC) Differential scanning calorimetry (DSC) experiments were performed using TA Instruments. TMThe measurements were performed on a model Q2000. Samples (approximately 1-6 mg) were weighed into an aluminum tray, recorded to the nearest 1 mg%, and transferred to the DSC. The instrument was purged with nitrogen gas at 50 mL / min. Data were collected between room temperature and 350°C at a heating rate of 10°C / min. The endothermic peak was plotted as it faced down. However, those skilled in the art have noticed that in DSC measurements, the observed onset and maximum temperatures have some variation depending on the heating rate, crystal shape and purity, and other measurement parameters.

[0041] 1.3, Thermogravimetric analysis (TGA) Thermogravimetric analysis (TGA) experiments were performed using TA Instruments TM The experiment was carried out on a Model Q500. Samples (approximately 10-30 mg) were placed in a pre-tared platinum tray. The instrument accurately measured the weight of the sample and recorded it to the nearest 1 mg‰. The furnace was purged with nitrogen gas at 100 mL / min. Data were collected from room temperature to 300 °C at a heating rate of 10 °C / min.

[0042] 1.4. Dynamic Vapor Sorption (DVS) The experimental method for characterizing the acid salt of the compound represented by the crystalline form (I) using dynamic vapor sorption (DVS) is to take a small amount of powder of the acid salt of the compound represented by the crystalline form (I) and place it in a precision sample pan that is set with the apparatus, and then load the sample and send it to the apparatus for measurement. All the apparatuses used for the dynamic vapor sorption in this patent are DVS Intrinsic models, and the experimental parameters are set to adopt nitrogen gas as the carrier gas, and the equilibrium reaching criteria are set to a constant temperature of 25°C and a mass percentage change rate per unit time (dm / dt) of 0.01% / min, and the humidity change program cycle is set to an initial relative humidity of 0% and an end relative humidity of 90%, with two cycles and a change in one step for every 10% RH.

[0043] The reagents in the embodiments of the present invention are known and commercially available as commercial industrial or analytical reagents. Alternatively, they can be synthesized using or according to methods known in the art, and the API raw materials can be produced according to patent WO2018113584A1.

[0044] Unless otherwise stated, all reactions of the present invention are carried out under a dry nitrogen or argon gas atmosphere with continuous magnetic stirring, solvents are dry solvents, and temperatures are in degrees Celsius (° C.). As used herein, the term "room temperature" or "RT" refers to an ambient temperature of 20-25° C. (68-77° F.).

[0045] The present invention will be described in more detail and completely by the following examples, which are used to describe only specific embodiments of the present invention and should not be construed as limiting the scope of the present invention in any manner.

[0046] Preparation of specific examples Example 1 Preparation of p-toluenesulfonate of compound represented by formula (I) 5 mg of the compound of formula (I) in free form was weighed and dissolved in 0.5 mL of ethyl acetate, 1.67 mg of p-toluenesulfonic acid was weighed and dissolved in 0.1 mL of tetrahydrofuran, and the p-toluenesulfonic acid solution was gradually added to the solution of the compound of formula (I) under stirring, stirred overnight, filtered, and the filter cake was dried in a vacuum drying box at 40° C. and characterized by DSC, TGA and XRPD. The DSC and TGA patterns of the obtained compound of formula (I) p-toluenesulfonate are shown in FIG. 1 and FIG. 2, respectively, and the XRPD diffraction pattern is shown in FIG. 3.

[0047] Example 2 Preparation of p-toluenesulfonate of compound represented by formula (I) 2 g of compound represented by formula (I) in free form is weighed and dissolved in 160 mL of ethyl acetate, 668 mg of p-toluenesulfonic acid is weighed and dissolved in 4 mL of tetrahydrofuran, the p-toluenesulfonic acid solution is gradually added to the solution of compound represented by formula (I) under stirring, stirred overnight, filtered, and the filter cake is dried in a vacuum drying box at 40° C., and the XRPD diffraction pattern of the compound represented by formula (I) p-toluenesulfonate is consistent with FIG. 3.

[0048] Example 3: Preparation of p-toluenesulfonate of compound represented by formula (I) 5 g of compound represented by formula (I) in free form is weighed out and dissolved / suspended in 400 mL of acetone, 1670 mg of p-toluenesulfonic acid is weighed out and dissolved in 10 mL of tetrahydrofuran, the p-toluenesulfonic acid solution is slowly added to the solution of compound represented by formula (I) with stirring, stirred overnight, filtered, and the filter cake is dried in a vacuum drying box at 40° C., and the XRPD diffraction pattern of compound represented by formula (I) p-toluenesulfonate is consistent with FIG. 3.

[0049] Example 4. Preparation and characterization of single crystals 150 mg of p-toluenesulfonate of the compound represented by formula (I) was weighed out, 1 mL of solvent (composition: methanol:ethanol = 1:1, plus 2% water) was added, and the mixture was stirred at 50 °C for 15 min. The suspension was filtered through a 0.45 μm filter, and the filtrate was used as the mother liquor. 340 μL of the mother liquor was taken, and 260 μL of solvent was added, and the mixture was mixed uniformly, cooled at room temperature, and recrystallized to obtain a single crystal.

[0050] A suitable single crystal was selected and detected on a Bruker APEX-II CCD single crystal diffractometer. The temperature was maintained at 220 K during the data collection period. The unit cell parameters of the compound p-toluenesulfonate represented by formula (I) are shown in Table 2, and the single crystal XRPD simulation results are consistent with the XRPD results of the compound p-toluenesulfonate represented by formula (I) as shown in Figure 4, and the unit cell structure of the single crystal is shown in Figure 5. Table 2:

[0051] [Table 2]

[0052] Example 5 Moisture absorption behavior test

[0053] The hygroscopicity of the compound p-toluenesulfonate (Form A) represented by formula (I) was evaluated by measuring the hygroscopic weight increase (hygroscopic weight increase / weight increase before hygroscopicity x 100%) at each relative humidity according to the dynamic water vapor adsorption method, and the results are shown in Figure 6. The experimental results show that the compound p-toluenesulfonate (Form A) represented by formula (I) of the present invention has a crystal weight change of basically 2% or less with an increase in relative humidity (%), has good hygroscopicity, meets the demands of industrial production, and can meet the demands of clinical formulation development.

[0054] Example 6 Stability Test The p-toluenesulfonate salt (Form A) of the compound represented by formula (I) and the free form of the compound represented by formula (I) were subjected to stability tests under high temperature and accelerated test conditions, and the stability of the p-toluenesulfonate salt (Form A) of the compound represented by formula (I) and the free form of the compound represented by formula (I) was evaluated using chemical purity as an evaluation index. The experimental results are shown in Table 3:

[0055] [Table 3]

[0056] The above experimental results show that the compound of the present invention is stable under high temperature and accelerated test conditions for 14 days, and the chemical stability of the product meets the needs of industrial production and clinical drug formulation development.

[0057] Example 7 Solubility Measurement 1) Solubility in water 2 mg of the p-toluenesulfonate salt (Form A) of the compound represented by formula (I) and 2 mg of the compound represented by formula (I) in free form were weighed into 2 mL glass bottles, and 0.4 mL of water was added to each glass bottle. The glass bottles were stirred with a magnetic stirrer at room temperature for 24 hours, centrifuged, and the content was measured in the liquid phase. The experimental results are shown in Table 4:

[0058] [Table 4]

[0059] From the above experimental results, it can be seen that the p-toluenesulfonate salt (Form A) of the compound represented by formula (I) has significantly higher solubility in water than the compound represented by formula (I) in free form, and can meet the needs of drug clinical formulation development. 2) Solubility in physiological solvents 80 mg of p-toluenesulfonate (Form A) of compound represented by formula (I) and 80 mg of compound represented by formula (I) in free form were weighed into 4 mL glass bottles, and 2 mL of solvent (25% PEG300 / 5% Solutol HS15 / 70% water) (v / v / v) was added to the glass bottles, respectively, and stirred with a magnetic stirrer at room temperature, and sampled at different times, centrifuged, and the content was measured in the liquid phase, and the results are shown in Figure 7. The experimental results show that the solubility of p-toluenesulfonate of compound represented by formula (I) is significantly higher than that of compound represented by formula (I) in free form, which can meet the demand for drug clinical formulation development.

[0060] Example 8: Pharmacokinetic studies in animals The p-toluenesulfonate salt (Form A) of the compound represented by formula (I) and the compound represented by formula (I) in free form were each subjected to a PK experiment in the body of a monkey at a dose of 200 mpk (amount as a free compound), and the experimental results are shown in Table 5:

[0061] [Table 5]

[0062] The above test results show that the p-toluenesulfonate of the compound represented by formula (I) can significantly increase the exposure of the compound represented by formula (I) in free form in the body of monkeys, and therefore the bioavailability of the compound represented by formula (I) in free form (Form A) is significantly higher than that of the compound represented by formula (I).

[0063] All documents related to the present invention are incorporated by reference in this application as if each document was incorporated individually. In addition, after reading the contents of the present invention, those skilled in the art may make various variations and modifications to the present invention, and it should be understood that these equivalent forms are also included in the scope of the claims attached to this application.

Claims

1. A p-toluenesulfonic acid salt of a compound represented by formula (I): 【Chemistry 1】

2. The compound p-toluenesulfonate represented by formula (I) is characterized in that it is a crystalline compound. A p-toluenesulfonic acid salt of the compound represented by formula (I) according to claim 1.

3. The X-ray powder diffraction pattern (XRPD) of the compound p-toluenesulfonate represented by the formula (I) includes peaks located at diffraction angles (2θ) of 9.02±0.2°, 17.18±0.2°, 17.68±0.2°, 19.60±0.2°, and 22.90±0.2°, and preferably, the X-ray powder diffraction pattern (XRPD) of the compound p-toluenesulfonate represented by the formula (I) includes peaks located at diffraction angles (2θ) of 10.60±0.2°, 12.72±0.2°, 13.0±0.2°, 14.0±0.2°, and 15.0±0.2°. and more preferably, the X-ray powder diffraction pattern (XRPD) of the compound p-toluenesulfonate represented by formula (I) further includes peaks located at diffraction angles (2θ) of 15.32±0.2°, 23.82±0.2°, 24.12±0.2°, 24.60±0.2°, and 25.58±0.2°. The p-toluenesulfonic acid salt of the compound represented by formula (I) according to claim 2.

4. The X-ray powder diffraction pattern of the compound p-toluenesulfonate represented by the formula (I) is 9.02±0.2°, 10.60±0.2°, 12.04±0.2°, 12.72±0.2°, 15.32±0.2°, 17.18±0.2°, 17.68±0.2°, 18.56±0.2°, 19.60±0.2°, 20.60±0.2°, 21.22±0.2°, 22.0±0.2°, 23.0±0.2°, 24.0±0.2°, 25.0±0.2°, 26.0±0.2°, 27.0±0.2°, 28.0±0.2°, 29.0±0.2°, 30.0±0.2°, 31.0±0.2°, 32.0±0.2°, 33.0±0.2°, 34.0±0.2°, 35.0±0.2°, 36.0±0.2°, 37.0±0.2°, 38.0±0.2°, 39.0±0.2°, 40.0±0.2°, 41.0±0.2°, 42.0±0.2°, 43.0±0.2°, 44.0±0.2°, 45.0±0.2°, 46.0±0.2°, 47.0±0.2°, 48.0±0.2°, 49.0±0.2°, 50.0±0.2°, 51.0±0.2°, 52.0±0.2°, 53.0±0.2°, 54 0.2°, 22.90±0.2°, 23.82±0.2°, 24.12±0.2°, 24.60±0.2°, 24.90±0.2°, 25.58±0.2°, 27.78±0.2°, 29.04±0.2°, 31.48±0.2°, 36.60±0.2° and 38.16±0.2°. The p-toluenesulfonic acid salt of the compound represented by formula (I) according to claim 2.

5. The unit cell of the compound p-toluenesulfonate represented by the formula (I) is P1, a = 9.079(3) Å, b = 10.561(3) Å, c = 10.882(3) Å, and the volume of the unit cell is 908.1(4) Å. 3 characterized in that A p-toluenesulfonic acid salt of the compound represented by formula (I) according to any one of claims 1 to 4.

6. The compound p-toluenesulfonate represented by formula (I) is a hydrate, preferably characterized in that each molecule of the hydrate contains 1 to 3 water molecules, more preferably characterized in that each molecule of the hydrate contains 1, 2 or 3 water molecules. A p-toluenesulfonic acid salt of the compound represented by formula (I) according to any one of claims 1 to 4.

7. A method for producing the p-toluenesulfonate salt of the compound represented by formula (I) according to claim 1, comprising the steps of: 1) a step of dissolving or dispersing the compound represented by formula (I) in a free form in an aqueous solvent or an appropriate organic solvent, and adding p-toluenesulfonic acid or a p-toluenesulfonic acid solution to the system to perform a salt formation reaction, or adding the compound represented by formula (I) in a free form to a p-toluenesulfonic acid solution to perform a salt formation reaction; 2) a step of collecting the p-toluenesulfonate of the compound represented by formula (I), which is a solid product precipitated during the reaction for forming the salt, or a step of obtaining the p-toluenesulfonate of the compound represented by formula (I), which is a solid product, by causing supersaturation in the salt formation system.

8. In the step 2), the method for generating supersaturation in the salt-forming system is selected from one or more of the following: addition of seed crystals, volatilization of a solvent, addition of a poor solvent, and lowering of temperature. The method of claim 7.

9. The suitable organic solvent used in step 1) is selected from the group consisting of alcohols, chloroalkanes, ketones, ethers, cyclic ethers, esters, alkanes, cycloalkanes, benzenes, amides, sulfoxides, or mixtures thereof. The method of claim 7.

10. The suitable organic solvent is selected from methanol, ethanol, n-propanol, isopropanol, dichloromethane, acetonitrile, acetone, 1,4-dioxane, tetrahydrofuran, N,N-dimethylformamide, ethyl acetate, isopropyl acetate, methyl-tert-butyl ether, 2-methoxyethyl ether or a mixture thereof. The method of claim 9.

11. A pharmaceutical composition comprising a therapeutically effective amount of a p-toluenesulfonic acid salt of a compound of formula (I) according to any one of claims 1 to 6 and a medicament acceptable carrier.

12. Use of the p-toluenesulfonate salt of the compound of formula (I) according to any one of claims 1 to 6 in the manufacture of an FGFR4 inhibitor drug.

13. Use of the p-toluenesulfonate salt of compound of formula (I) according to any one of claims 1 to 6 in the manufacture of a medicament for treating liver cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma or rhabdomyosarcoma.

14. 1. A method of treating liver cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma, or rhabdomyosarcoma, comprising: The method comprises administering to a patient in need of treatment a therapeutically effective amount of the p-toluenesulfonate salt of compound of formula (I) according to any one of claims 1 to 6, or the pharmaceutical composition according to claim 11.

Citation Information

Patent Citations

  • FGFR4 inhibitor and preparation method and application thereof

    CN109745325A

  • FGFR4 kinase inhibitor, preparation method and uses thereof

    CN110950867A

  • Medicine containing aminopyrazole derivative

    JP2012180344A

  • FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof

    WO2018113584A1

  • The salts of a compound and the crystalline forms thereof

    WO2021073494A1